Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Single-Use Bioreactor Now Accommodates Wide Range of Working Volumes

By BiotechDaily International staff writers
Posted on 24 Jun 2013
Image: The UniVessel SU (right) can work in parallel with classical multiuse reaction bioreactor vessels (Photo courtesy of Sartorius Stedim Biotech).
Image: The UniVessel SU (right) can work in parallel with classical multiuse reaction bioreactor vessels (Photo courtesy of Sartorius Stedim Biotech).
Image: The UniVessel SU is preassembled and ready-to-use out of the box (Photo courtesy of Sartorius Stedim Biotech).
Image: The UniVessel SU is preassembled and ready-to-use out of the box (Photo courtesy of Sartorius Stedim Biotech).
The second generation of a highly regarded single-use bioreactor vessel with built-in pH and dissolved oxygen sensors suitable for work with mammalian, insect, and plant cell cultures was recently released for researchers in biopharmaceuticals and other life sciences.

The Sartorius Stedim Biotech (Aubagne, France) UniVessel SU is a single-use bioreactor with a choice of working volumes ranging from 0.6 to two liters. The vessel is made of USP class VI conforming polycarbonate and includes several ports for media addition, sampling, harvesting, as well as spare ports for insertion of classical sensors or other equipment. All tubing for media transfer is thermoweldable and features common Luer or MPC connectors for fast and easy connection to peripheral equipment.

Key features of the UniVessel SU are the single-use sensors for optical measurement of pH and dissolved oxygen (DO). The determination of pH and DO with the SENSOLUX system is based on fluorescence detection. Each UniVessel SU contains two sensor patches for pH and DO, respectively. The actual measurement is performed optically and noninvasively from outside the vessel. The sensor patches contain fluorescent dyes, which can be excited with light of a given wavelength. Optoelectronics integrated in the vessel holder transmit light of a particular wavelength to the sensor patches. In turn, they also transmit the luminescence response from the patches to a measuring amplifier. The sensor patches inside the UniVessel SU come precalibrated. Calibration data are located on the vessel label and can be transferred manually or by barcode reader to the calibration menu of the bioreactor controller. UniVessel SU is compatible with Sartorius BIOSTAT controllers and can also be operated with nearly any other brand of bioreactor controller.

Each UniVessel SU unit is irradiated prior to delivery and is preassembled and ready-to-use out of the box. It is designed to the same safety standards, which are required for classical multiuse bioreactors. The complete culture vessel is disposed after use, eliminating cleaning time, autoclaving, and reinstallation hassle as well as the risk of cross-contamination.

Related Links:
Sartorius Stedim Biotech




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.